nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR4—female reproductive system—fallopian tube cancer	0.0309	0.0309	CbGeAlD
Ponatinib—FGFR3—epithelium—fallopian tube cancer	0.0284	0.0284	CbGeAlD
Ponatinib—FGFR3—uterine cervix—fallopian tube cancer	0.0282	0.0282	CbGeAlD
Ponatinib—FGFR4—female gonad—fallopian tube cancer	0.0282	0.0282	CbGeAlD
Ponatinib—BCR—uterine cervix—fallopian tube cancer	0.0244	0.0244	CbGeAlD
Ponatinib—BCR—endometrium—fallopian tube cancer	0.0221	0.0221	CbGeAlD
Ponatinib—FGFR1—uterine cervix—fallopian tube cancer	0.0217	0.0217	CbGeAlD
Ponatinib—FGFR3—female reproductive system—fallopian tube cancer	0.0211	0.0211	CbGeAlD
Ponatinib—BCR—uterus—fallopian tube cancer	0.0203	0.0203	CbGeAlD
Ponatinib—RET—epithelium—fallopian tube cancer	0.0196	0.0196	CbGeAlD
Ponatinib—LCK—uterine cervix—fallopian tube cancer	0.0194	0.0194	CbGeAlD
Ponatinib—FGFR2—epithelium—fallopian tube cancer	0.0186	0.0186	CbGeAlD
Ponatinib—FGFR2—uterine cervix—fallopian tube cancer	0.0184	0.0184	CbGeAlD
Ponatinib—BCR—female reproductive system—fallopian tube cancer	0.0183	0.0183	CbGeAlD
Ponatinib—FLT3—female reproductive system—fallopian tube cancer	0.0181	0.0181	CbGeAlD
Ponatinib—FGFR1—uterus—fallopian tube cancer	0.0181	0.0181	CbGeAlD
Ponatinib—TEK—epithelium—fallopian tube cancer	0.0178	0.0178	CbGeAlD
Ponatinib—BCR—female gonad—fallopian tube cancer	0.0166	0.0166	CbGeAlD
Ponatinib—BCR—vagina—fallopian tube cancer	0.0165	0.0165	CbGeAlD
Ponatinib—FLT3—female gonad—fallopian tube cancer	0.0165	0.0165	CbGeAlD
Ponatinib—LCK—uterus—fallopian tube cancer	0.0162	0.0162	CbGeAlD
Ponatinib—TEK—endometrium—fallopian tube cancer	0.016	0.016	CbGeAlD
Ponatinib—SRC—epithelium—fallopian tube cancer	0.0158	0.0158	CbGeAlD
Ponatinib—SRC—uterine cervix—fallopian tube cancer	0.0157	0.0157	CbGeAlD
Ponatinib—FGFR2—uterus—fallopian tube cancer	0.0154	0.0154	CbGeAlD
Ponatinib—FGFR1—female gonad—fallopian tube cancer	0.0148	0.0148	CbGeAlD
Ponatinib—TEK—uterus—fallopian tube cancer	0.0147	0.0147	CbGeAlD
Ponatinib—FGFR1—vagina—fallopian tube cancer	0.0147	0.0147	CbGeAlD
Ponatinib—KDR—epithelium—fallopian tube cancer	0.0146	0.0146	CbGeAlD
Ponatinib—KDR—uterine cervix—fallopian tube cancer	0.0145	0.0145	CbGeAlD
Ponatinib—FGFR2—female reproductive system—fallopian tube cancer	0.0138	0.0138	CbGeAlD
Ponatinib—PDGFRA—uterus—fallopian tube cancer	0.0134	0.0134	CbGeAlD
Ponatinib—TEK—female reproductive system—fallopian tube cancer	0.0133	0.0133	CbGeAlD
Ponatinib—LCK—female gonad—fallopian tube cancer	0.0132	0.0132	CbGeAlD
Ponatinib—LCK—vagina—fallopian tube cancer	0.0132	0.0132	CbGeAlD
Ponatinib—KDR—endometrium—fallopian tube cancer	0.0131	0.0131	CbGeAlD
Ponatinib—KIT—epithelium—fallopian tube cancer	0.0129	0.0129	CbGeAlD
Ponatinib—KIT—uterine cervix—fallopian tube cancer	0.0128	0.0128	CbGeAlD
Ponatinib—FGFR2—female gonad—fallopian tube cancer	0.0126	0.0126	CbGeAlD
Ponatinib—TEK—female gonad—fallopian tube cancer	0.0121	0.0121	CbGeAlD
Ponatinib—KDR—uterus—fallopian tube cancer	0.012	0.012	CbGeAlD
Ponatinib—PDGFRA—female reproductive system—fallopian tube cancer	0.012	0.012	CbGeAlD
Ponatinib—SRC—female reproductive system—fallopian tube cancer	0.0118	0.0118	CbGeAlD
Ponatinib—KIT—endometrium—fallopian tube cancer	0.0116	0.0116	CbGeAlD
Ponatinib—ABL1—uterine cervix—fallopian tube cancer	0.0112	0.0112	CbGeAlD
Ponatinib—PDGFRA—female gonad—fallopian tube cancer	0.0109	0.0109	CbGeAlD
Ponatinib—PDGFRA—vagina—fallopian tube cancer	0.0109	0.0109	CbGeAlD
Ponatinib—KDR—female reproductive system—fallopian tube cancer	0.0108	0.0108	CbGeAlD
Ponatinib—SRC—female gonad—fallopian tube cancer	0.0107	0.0107	CbGeAlD
Ponatinib—KIT—uterus—fallopian tube cancer	0.0107	0.0107	CbGeAlD
Ponatinib—ABL1—endometrium—fallopian tube cancer	0.0101	0.0101	CbGeAlD
Ponatinib—KDR—female gonad—fallopian tube cancer	0.00985	0.00985	CbGeAlD
Ponatinib—KDR—vagina—fallopian tube cancer	0.00979	0.00979	CbGeAlD
Ponatinib—KIT—female reproductive system—fallopian tube cancer	0.0096	0.0096	CbGeAlD
Ponatinib—ABL1—uterus—fallopian tube cancer	0.00929	0.00929	CbGeAlD
Ponatinib—KIT—female gonad—fallopian tube cancer	0.00873	0.00873	CbGeAlD
Ponatinib—KIT—vagina—fallopian tube cancer	0.00868	0.00868	CbGeAlD
Ponatinib—ABL1—female reproductive system—fallopian tube cancer	0.00835	0.00835	CbGeAlD
Ponatinib—ABL1—female gonad—fallopian tube cancer	0.0076	0.0076	CbGeAlD
Ponatinib—ABL1—vagina—fallopian tube cancer	0.00756	0.00756	CbGeAlD
Ponatinib—ABCG2—uterine cervix—fallopian tube cancer	0.00703	0.00703	CbGeAlD
Ponatinib—CYP2C8—endometrium—fallopian tube cancer	0.00654	0.00654	CbGeAlD
Ponatinib—CYP3A5—uterine cervix—fallopian tube cancer	0.00653	0.00653	CbGeAlD
Ponatinib—ABCG2—endometrium—fallopian tube cancer	0.00636	0.00636	CbGeAlD
Ponatinib—ABCG2—uterus—fallopian tube cancer	0.00586	0.00586	CbGeAlD
Ponatinib—CYP2C8—female reproductive system—fallopian tube cancer	0.00542	0.00542	CbGeAlD
Ponatinib—CYP2C8—vagina—fallopian tube cancer	0.0049	0.0049	CbGeAlD
Ponatinib—ABCG2—female gonad—fallopian tube cancer	0.00479	0.00479	CbGeAlD
Ponatinib—ABCG2—vagina—fallopian tube cancer	0.00477	0.00477	CbGeAlD
Ponatinib—CYP3A5—female gonad—fallopian tube cancer	0.00445	0.00445	CbGeAlD
Ponatinib—CYP3A5—vagina—fallopian tube cancer	0.00442	0.00442	CbGeAlD
Ponatinib—CYP3A4—female reproductive system—fallopian tube cancer	0.00367	0.00367	CbGeAlD
Ponatinib—CYP2D6—female reproductive system—fallopian tube cancer	0.00361	0.00361	CbGeAlD
Ponatinib—ABCB1—epithelium—fallopian tube cancer	0.0035	0.0035	CbGeAlD
Ponatinib—ABCB1—uterine cervix—fallopian tube cancer	0.00347	0.00347	CbGeAlD
Ponatinib—CYP2D6—female gonad—fallopian tube cancer	0.00329	0.00329	CbGeAlD
Ponatinib—ABCB1—endometrium—fallopian tube cancer	0.00314	0.00314	CbGeAlD
Ponatinib—ABCB1—uterus—fallopian tube cancer	0.00289	0.00289	CbGeAlD
Ponatinib—ABCB1—female reproductive system—fallopian tube cancer	0.0026	0.0026	CbGeAlD
Ponatinib—ABCB1—female gonad—fallopian tube cancer	0.00236	0.00236	CbGeAlD
Ponatinib—ABCB1—vagina—fallopian tube cancer	0.00235	0.00235	CbGeAlD
